|
|
|||||||||||
SHORT REPORTS |
Sheffield Cognition and Neuroimaging Laboratory (SCANLab), Academic Clinical Psychiatry, University of Sheffield, UK
Correspondence: Dr Tom F. D. Farrow, SCANLab, Academic Clinical Psychiatry, University of Sheffield, The Longley Centre, Northern General Hospital, Norwood Grange Drive, Sheffield S5 7JT, UK. Email: t.f.farrow{at}sheffield.ac.uk
Declaration of interest This study was funded by a grant awarded to S.A.S. by Cephalon UK, the manufacturers of modafinil. The sponsor was involved in the study design, but had no role in data collection, analysis, the writing of the reportor the decision to submit the paper for publication.
Avolition affects quality of life in chronic schizophrenia. We investigated the effect of modafinil upon unconstrained motor activity in 18 male patients. In a randomised crossover design study, wrist-worn actigraphic monitors were used to objectively record motor activity over a 20 h period. Patients total activity was significantly greater when given the drug. These data suggest that modafinil increases quantifiable motor behaviour in schizophrenia and may have an impact on avolition.
This article has been cited by other articles:
![]() |
S. Morein-Zamir, D. C. Turner, and B. J. Sahakian A Review of the Effects of Modafinil on Cognition in Schizophrenia Schizophr Bull, November 1, 2007; 33(6): 1298 - 1306. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Psychiatric Bulletin | Advances in Psychiatric Treatment | All RCPsych Journals |